Fig. 1: Patient flow diagram.
The FAS included all patients who had received any IMP. The PP population comprised all patients who had received >3 doses of atezolizumab/placebo and >2 doses of PLD and could be evaluated for tumor response.
Fig. 1: Patient flow diagram. | Nature Medicine
